when you read this (Aust Fin Review 19/01), it really does make you proud to be part of this company:-
Revascor is used to treat hypoplastic left heart syndrome (HLHS), a severe congenital heart disease in which one side of the heart does not fully develop. The condition is responsible for between 25 per cent to 40 per cent of newborn cardiac deaths.
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-191
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |